Markets:

Overview

News

Currencies

International

Treasuries

Royal Bank of Canada (TSX:RY)

264.66 +2.69 (+1.03%)

Streaming Delayed Price Updated: 10:19 AM EDT, May 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Royal Bank of Canada

< Previous 1 2 3 4 5 6 7 8 9

...

40 41 Next >

3 Market-Beating Stocks on Our Watchlist

Today 0:39 EDT

Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca...

Via StockStory

Topics Artificial Intelligence

2 Stocks That Could Turn $100,000 Into $1 Million ↗

May 24, 2026

Two stocks and an income-and-growth strategy could turn $100,000 into a seven-figure fortune over time.

Via The Motley Fool

Topics Artificial Intelligence

Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference ↗

May 24, 2026

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC...

Via MarketBeat

Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near ↗

May 23, 2026

Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president...

Via MarketBeat

A Perfect TFSA Pair for 2026: 2 Stocks I’d Buy Now ↗

May 22, 2026

Royal Bank of Canada (TSX:RY) and another great pick for a TFSA fund.

Via The Motley Fool

Topics Artificial Intelligence

Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise ↗

May 22, 2026

Cytokinetics (NASDAQ:CYTK) executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug’s label, REMS...

Via MarketBeat

Are Wall Street Analysts Predicting Cboe Global Markets Stock Will Climb or Sink?

May 22, 2026

Cboe Global Markets has considerably outperformed the broader market over the past 52 weeks, yet Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Via Barchart.com

Topics Derivatives ETFs

Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential ↗

May 22, 2026

Contineum Therapeutics (NASDAQ:CTNM) President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent...

Via MarketBeat

Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout ↗

May 22, 2026

Corbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Officer Yuval Cohen said investors should expect more mature clinical updates for CRB-701 at the upcoming ASCO meeting, including the first...

Via MarketBeat

5 Must-Read Analyst Questions From RBC Bearings’s Q1 Earnings Call

May 22, 2026

RBC Bearings delivered first quarter results that surpassed Wall Street’s revenue and non-GAAP profit expectations, but the market responded negatively. Mana...

Via StockStory

Topics Earnings

Sprout Social and Veeva Systems Shares Plummet, What You Need To Know

May 21, 2026

What Happened? A number of stocks fell in the afternoon session after Intuit's plunge spread across the sector and reignited the thesis that generative AI is...

Via StockStory

Topics Artificial Intelligence

Asana, Atlassian, and BlackLine Shares Are Falling, What You Need To Know

May 21, 2026

What Happened? A number of stocks fell in the afternoon session after Intuit's plunge spread across the sector and reignited the thesis that generative AI is...

Via StockStory

Topics Artificial Intelligence

Are Wall Street Analysts Predicting IQVIA Holdings Stock Will Climb or Sink?

May 21, 2026

While IQVIA Holdings has lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Via Barchart.com

Topics ETFs

Dear F5 Stock Fans, Mark Your Calendars for May 28

May 21, 2026

Upcoming analyst day is likely to provide further insights on AI-driven growth momentum.

Via Barchart.com

Topics Artificial Intelligence Earnings

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference ↗

May 20, 2026

CG Oncology (NASDAQ:CGON) executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company’s investigational therapy for non-muscle invasive bladder...

Via MarketBeat

Topics Initial Public Offering

1 Top Dividend Stock to Buy and Hold for 10 Years ↗

May 20, 2026

A monthly dividend stock with assured demand and business growth fits a 10-year investment horizon.

Via The Motley Fool

Topics Artificial Intelligence

The #1 Stock I’d Keep Forever Inside a TFSA ↗

May 20, 2026

A renewable energy powerhouse with visible business growth potential is an ideal lifelong investment for a TFSA.

Via The Motley Fool

Topics Artificial Intelligence Retirement

Lattice Semiconductor (LSCC) Shares Skyrocket, What You Need To Know

May 20, 2026

What Happened? Shares of semiconductor designer Lattice Semiconductor (NASDAQ:LSCC) jumped 9.7% in the afternoon session after CEO Ford Tamer's presentation ...

Via StockStory

Topics Artificial Intelligence Government

Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances ↗

May 20, 2026

Beam Therapeutics (NASDAQ:BEAM) Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics...

Via MarketBeat

Topics Intellectual Property

Why Are GE Aerospace (GE) Shares Soaring Today

May 20, 2026

What Happened? Shares of industrial conglomerate GE Aerospace (NYSE:GE) jumped 5% in the afternoon session after the company secured a U.S. Air Force contrac...

Via StockStory

Topics Bonds Economy

2 Canadian Stocks Primed to Surge in 2026 ↗

May 20, 2026

Two Canadian stocks with powerful fundamental catalysts are poised to deliver exceptional gains in 2026.

Via The Motley Fool

Topics Artificial Intelligence

Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum ↗

May 20, 2026

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in...

Via MarketBeat

Are Wall Street Analysts Predicting Church & Dwight Stock Will Climb or Sink?

May 20, 2026

Church & Dwight has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Via Barchart.com

Topics ETFs

Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances ↗

May 19, 2026

Agios Pharmaceuticals (NASDAQ:AGIO) executives said the company is focused on advancing mitapivat across rare hematologic diseases, highlighting early launch traction in thalassemia and a recently...

Via MarketBeat

ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth ↗

May 19, 2026

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide...

Via MarketBeat

Addus HomeCare Says License Moratorium Won’t Slow Personal Care Growth, M&A ↗

May 19, 2026

Addus HomeCare (NASDAQ:ADUS) executives said a new federal moratorium on certain home health licenses should have little effect on the company’s growth plans, while highlighting continued improvement...

Via MarketBeat

The Top 3 Canadian ETFs I’m Considering for 2026 ↗

May 18, 2026

The top three Canadian ETFs are reliable passive monthly income providers to investors seeking instant diversification.

Via The Motley Fool

Topics Artificial Intelligence ETFs

3 TSX Stocks Built for Higher-for-Longer Interest Rates ↗

May 18, 2026

Three TSX stocks are strong buys if a higher-for-longer interest rate environment is forthcoming.

Via The Motley Fool

Topics Artificial Intelligence Economy

Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.

May 18, 2026

Regeneron stock sinks as fianlimab Phase 3 trial fails to meet primary endpoint. But RBC continues to see significant upside in REGN shares from here.

Via Barchart.com

Do Wall Street Analysts Like Thermo Fisher Scientific Stock?

May 18, 2026

While Thermo Fisher Scientific has considerably underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.

Via Barchart.com

Topics ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

40 41 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.